Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | TPH1 | P17752 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CSK | P41240 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870353 | 1.00 | SLC7A5 (0.50) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL918401 | 0.83 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL43851 | 0.83 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL17750404 | 0.83 | SLC7A5 (0.50) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL358908 | 0.83 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL288375 | 0.83 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL3241485 | 0.83 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL43852 | 0.83 | SLC7A5 (0.71) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL13696626 | 0.83 | SLC7A5 (0.50) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12324618 | 0.82 | EPHX1 (0.56) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020220-A1 | COMPOUNDS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | claimed |
| EP-3500252-B1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO BIO LTD (GB) | 2022-11-02 | — | — | EP | disclosed |
| US-20210094983-A1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO-BIO LTD. (GB) | 2021-04-01 | — | — | US | disclosed |
| WO-2012020220-A1 | COMPOUNDS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-7538182-B2 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070037967-A1 | conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7129327-B2 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040081660-A1 | Polypeptide and protein derivatives and process for their preparation | AMYLIN PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6673347-B1 | CONJUGATED TO POLYMER VIA SCHIFF BASE, HYDRAZONE, OXIME, OR AZOMETHINE COMPOUND; DIAGNOSING TUMORS AND METASTASIS | GRYPHON THERAPEUTICS | 2004-01-06 | — | — | US | disclosed |
| EP-0243929-B1 | Polypeptide and protein derivatives and process for their preparation | OFFORD ROBIN EWART (CH) | 1995-09-27 | — | — | EP | disclosed |
| EP-0495013-B1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORP (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0226217-B1 | Peptides with sulfate ester group | FISONS CORP (US) | 1994-01-26 | — | — | EP | disclosed |
| EP-0495013-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS. | FISONS CORP (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991008225-A1 | HEXAPEPTIDES WITH SULPHATE ESTER GROUPS | FISONS CORPORATION (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0243929-A2 | Polypeptide and protein derivatives and process for their preparation | Offord, Robin Ewart (CH) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037967-A1 | conjugated by bridging molecules to proteins or polypeptides, reporter groups or cytotoxic agents; cancer | HDGFL3, HCCS, HDGF | SLC7A5 1365/4885PTGS1 2395/4885ALPI 4019/4885 |
| US-20210094983-A1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | IAPP, NLN, APP | SLC7A5 3290/4885PTGS1 3071/4885ALPI 4722/4885 |
| US-20040081660-A1 | Polypeptide and protein derivatives and process for their preparation | INSRR, GIPR, HM13 | SLC7A5 1133/4885PTGS1 3071/4885ALPI 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.